Keros Therapeutics reports Q3 2023 net loss of $39.4M; advances KER-050, deprioritizes KER-047

Keros Therapeutics, Inc.

2023-Q3 EPS reported -$3.86 revenue$8,000

Net loss of $39.4M in Q3 2023 vs $23.5M in Q3 2022, driven by increased R&D spending.
R&D expenses rose to $34.1M from $21.0M; G&A rose to $9.1M from $6.9M.
Cash and equivalents of $287.9M provide runway into Q4 2025.
KER-047 program deprioritized; Phase 2 trial in MDS/myelofibrosis being terminated early.
KER-065 Phase 1 trial in healthy adults expected to start in Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Keros Therapeutics, Inc. reported for the quarter ended September 30, 2023 results: net income net loss of $39.4 million.

Period: for the quarter ended September 30, 2023
Net income: net loss of $39.4 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $39.4 million in the third quarter of 2023 as compared to a net loss of $23.5 million in the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-23-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.